In the first study leveraging the 38C13-hCD38 tumor model and evaluating hCD38-mAtt activity, hCD38-directed binding was only possible to hCD38 exclusively expressed on these engineered tumor cells. This evidence concerns the gene TMEM79 and neoplasm.